Showing results (41-50 of 125) with videos related to

Sort By:
Pageof 13
Molecular Cancer Therapeutics|December 3, 2011
Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancerHyun-Jin Nam, Keith A Ching, Julie Kan, et al.
Plos One|June 30, 2012
A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activationNathan V Lee, Maruja E Lira, Adam Pavlicek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET InhibitionThomas Bachleitner-Hofmann, Mark Y Sun, Chin-Tung Chen, et al.
Molecular Cancer Therapeutics|July 5, 2012
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinibOndrej Kalous, Dylan Conklin, Amrita J Desai, et al.
Genes, Chromosomes & Cancer|August 19, 2008
Expression and mutational analysis of MET in human solid cancersPatrick C Ma, Maria S Tretiakova, Alexander C MacKinnon, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2006
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Gromoslaw A Smolen, Raffaella Sordella, Beth Muir, et al.
Cancer Discovery|May 16, 2012
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumorsBarbara Sennino, Toshina Ishiguro-Oonuma, Ying Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2023
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS MetastasesMarcelo V Negrao, Alexander I Spira, Rebecca S Heist, et al.
Future Oncology (London, England)|November 29, 2019
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancerJeffrey W Clark, D Ross Camidge, Eunice L Kwak, et al.
Lung Cancer (Amsterdam, Netherlands)|February 28, 2024
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterationsDavid S Hong, Federico Cappuzzo, Byoung Chul Cho, et al.
Pageof 13